AIP operates through three primary mechanisms:
AhR signaling regulation: Enhances ligand receptivity and nuclear targeting of the aryl hydrocarbon receptor
Chaperone activity: Forms complexes with Hsp90 to stabilize client proteins like AhR and peroxisome proliferator-activated receptor alpha
Tumor suppression: Reduces cell proliferation via interactions with RET proto-oncogene and phosphodiesterase PDE4A5
Notably, AIP co-localizes with growth hormone (GH) in somatotroph secretory vesicles but circulates independently of GH under basal or stimulated conditions .
AIP dysfunction is linked to:
Familial pituitary adenomas: 20% of mutation carriers develop growth hormone-secreting tumors by age 30
Acromegaly: 50% of AIP mutation-associated adenomas show GH hypersecretion
Antiviral response suppression: Interaction with IRF7 inhibits type I interferon production
The human recombinant form (PRO-886) serves as a critical tool for:
AH receptor-interacting protein, AIP, Aryl-hydrocarbon receptor-interacting protein, HBV X-associated protein 2, XAP-2, Immunophilin homolog ARA9, XAP2, ARA9, FKBP16, FKBP37, SMTPHN.
MGSSHHHHHH SSGLVPRGSH MADIIARLRE DGIQKRVIQE GRGELPDFQD GTKATFHYRT LHSDDEGTVL DDSRARGKPM ELIIGKKFKL PVWETIVCTM REGEIAQFLC DIKHVVLYPL VAKSLRNIAV GKDPLEGQRH CCGVAQMREH SSLGHADLDA LQQNPQPLIF HMEMLKVESP
GTYQQDPWAM TDEEKAKAVP LIHQEGNRLY REGHVKEAAA KYYDAIACLK NLQMKEQPGS PEWIQLDKQI TPLLLNYCQC KLVVEEYYEV LDHCSSILNK YDDNVKAYFK RGKAHAAVWN AQEAQADFAK VLELDPALAP VVSRELRALE ARIRQKDEED KARFRGIFSH.
AIP is a genetic disorder caused by a partial deficiency of the enzyme porphobilinogen deaminase (PBGD), also known as hydroxymethylbilane synthase (HMBS). This enzyme plays a critical role in heme production, and its deficiency leads to the accumulation of precursor molecules that can cause AIP attacks. Research methodologies typically include enzyme activity assays, genetic sequencing of the HMBS gene, and biochemical analysis of porphyrin precursors in urine and blood. Experimental models employ both cell culture systems with HMBS mutations and transgenic animal models to study the pathophysiological mechanisms of AIP .
Researchers employ multiple methodological approaches to differentiate between overt AIP (symptomatic) and latent AIP (asymptomatic carriers). The primary distinction involves:
Clinical history assessment: Documentation of previous acute attacks with characteristic symptoms
Biochemical markers: Quantification of urinary porphobilinogen (PBG) levels, which are significantly elevated during attacks
Genetic testing: Identification of HMBS gene mutations
Challenge tests: In some research protocols, controlled administration of potential triggers under medical supervision
For research cohort stratification, individuals with documented attacks are classified as having overt AIP, while those with confirmed HMBS mutations but no clinical manifestations are classified as having latent AIP .
Investigating AIP triggers presents several methodological challenges:
Temporal relationship complexity: Multiple simultaneous triggers often precede attacks, making causality difficult to establish
Individual variability: The threshold for triggering varies significantly between patients
Ethical limitations: Deliberate provocation testing is generally contraindicated due to potential harm
Retrospective bias: Patient recall of pre-attack circumstances may be unreliable
Researchers address these challenges through prospective diary studies, biomarker monitoring (urinary PBG measurements), and case-control studies comparing environmental exposures and medication use during attack and non-attack periods .
Research methodologies for studying AIP inheritance include:
Pedigree analysis: Documenting the autosomal dominant inheritance pattern where offspring have a 50% chance of inheriting the mutation when one parent carries the mutation.
Genetic sequencing: Identifying specific HMBS gene mutations, which can vary between families.
Penetrance studies: Investigating why most individuals with mutations remain asymptomatic (latent AIP), focusing on genetic modifiers and environmental factors.
Genotype-phenotype correlation: Examining whether specific mutations correlate with clinical severity or attack frequency .
Approval-In-Principle (AIP) is a regulatory mechanism established under 45 CFR 46.118 to facilitate review of research proposals that lack definite plans for human subject involvement at the time of application. This framework is specifically designed for studies where human participation will occur in later phases contingent upon preliminary development activities. AIPs function as a provisional approval that acknowledges the eventual human subjects component while recognizing that detailed protocols cannot yet be formulated .
Under AIP approval, researchers may conduct:
Development of research instruments and survey tools
Refinement of experimental compounds
Preliminary animal studies
Creation of study protocols and statistical analysis plans
Establishment of laboratory procedures
Prohibited activities under AIP include:
Any direct human subjects recruitment
Obtaining informed consent
Research interactions or interventions with human participants
Collection of human biological samples
Analysis of identifiable private information
Pilot testing with human subjects
An AIP serves as a framework for preliminary research activities that must be completed before human subjects involvement can be appropriately designed and implemented .
The methodological progression from AIP to full IRB approval involves:
Completion of developmental phase: Document all preliminary work conducted under the AIP
Protocol finalization: Develop detailed research procedures based on preliminary findings
Risk assessment: Evaluate potential risks to participants based on finalized methods
IRB submission: Prepare comprehensive documentation including:
Detailed study protocol
Informed consent documents
Recruitment materials
Data safety monitoring plans
Instruments and measures
Regulatory response: Address IRB questions and concerns
Approval implementation: Transition from developmental to active human research
This transition requires explicit documentation of how preliminary work informed the final protocol design and how any potential risks identified during development will be mitigated .
Research on the anterior intraparietal area (AIP) employs multiple neuroimaging approaches, with functional magnetic resonance imaging (fMRI) being the predominant method. Task-based fMRI using visually guided hand movement paradigms and 3D object discrimination tasks has effectively localized AIP. Researchers typically employ:
Block design protocols: Alternating periods of AIP-targeted tasks with control conditions
Event-related designs: Isolating specific cognitive components of grasping or object recognition
Retinotopic mapping: Establishing relationships to nearby visual processing regions
Multimodal approaches: Combining fMRI with MEG or EEG for temporal precision
Reliable anatomical landmarks place human AIP at the junction of the anterior intraparietal sulcus and the postcentral sulcus, with subject-level localization being crucial due to individual anatomical variability .
Differentiating between anterior (AIP), caudal (CIP), and lateral (LIP) intraparietal areas requires precise methodological approaches:
| Area | Primary Function | Task Paradigm | Anatomical Landmark |
|---|---|---|---|
| AIP | Visually guided hand movements, grasping | Object manipulation, 3D feature processing | Rostral part of lateral bank of anterior IPS |
| CIP | Surface orientation processing, depth perception | Surface orientation discrimination | Medial side branch of posterior IPS |
| LIP | Saccadic eye movements, spatial attention | Memory-guided saccades, spatial working memory | Middle region of IPS |
Researchers employ differential task activation patterns to distinguish these functionally specialized regions. For example, studies use delayed matching-to-sample tasks with orientation judgments to activate CIP, while memory-guided saccadic eye movement tasks activate LIP. Eye movement recording during scanning ensures task compliance and helps differentiate activation related to hand movements from that related to eye movements .
Translating AIP research from non-human primates to humans presents several methodological challenges:
Anatomical differences: Human IPS shows greater complexity and individual variability compared to non-human primates
Functional homology uncertainty: While functionally similar, human and non-human primate AIP may not be perfectly homologous
Experimental design constraints: Tasks optimized for non-human primates often require modification for human participants
Resolution limitations: Single-unit recordings in non-human primates provide cellular-level data unavailable in typical human studies
Research groups address these challenges through:
Conducting parallel experiments with matched task designs
Employing high-field MRI for improved spatial resolution
Using multivariate pattern analysis to detect fine-grained activation patterns
Developing naturalistic tasks that can be performed similarly by both humans and non-human primates
Current research indicates functional specialization within human AIP for processing different aspects of object-directed actions:
Ventral-dorsal organization: Ventral regions primarily process object properties (shape, size), while dorsal regions process action parameters (grip type, force)
Temporal dynamics: Early activation relates to object recognition, while later activation relates to motor planning
Connectivity patterns: Different AIP subregions show preferential connectivity with either ventral visual areas or motor planning regions
Studies employing high-resolution fMRI have revealed that AIP activation is not homogeneous but shows task-specific patterns. For example, discrimination of object orientation engages different AIP subregions than grasping movements directed toward the same objects. This functional organization appears to support the transformation of visual information into appropriate hand configurations for object interaction .
Interdisciplinary AIP research requires methodological frameworks that bridge different research domains:
Standardized terminology: Developing clear terminology distinguishing AIP contexts to avoid confusion in literature searches and citations
Cross-domain collaborative teams: Involving experts from genetics, neuroscience, and clinical medicine in research design
Comprehensive protocol design: Accounting for potential confounding variables across domains
Integrated data management: Creating systems that accommodate diverse data types from various methodological approaches
Successful interdisciplinary studies typically employ mixed-methods approaches that integrate quantitative measurements with qualitative insights from different disciplinary perspectives .
Ethical considerations vary significantly across AIP contexts:
For Acute Intermittent Porphyria studies:
Genetic privacy and implications for family members
Risk management during research participation
Access to emergency treatments during studies
For Approval-In-Principle human research:
Maintaining clear boundaries before human subjects involvement
Ensuring preparedness for ethical human subjects research
Transparent communication with regulatory bodies
For Anterior Intraparietal Area neuroscience research:
Balancing task complexity with participant comfort
Managing incidental neurological findings
Ensuring data privacy in brain imaging repositories
Researchers should develop context-specific ethical frameworks while adhering to core principles of autonomy, beneficence, non-maleficence, and justice across all AIP domains .
Across all AIP contexts, technological and methodological innovations are advancing research capabilities:
For Acute Intermittent Porphyria:
Gene editing approaches for potential therapeutic applications
Longitudinal biomarker studies using wearable monitoring technology
Systems biology approaches integrating metabolomic and genomic data
For Approval-In-Principle processes:
Digital tracking systems for developmental research phases
Harmonized international regulatory frameworks
Adaptive protocol designs that evolve from AIP to full IRB approval
For Anterior Intraparietal Area neuroscience:
Ultra-high field neuroimaging (7T and higher)
Combined TMS-fMRI approaches for causality assessment
Computational modeling of AIP networks in sensorimotor control
These emerging methodologies promise to address current research limitations while opening new avenues for investigation across all AIP domains .
Researchers should employ systematic approaches to resolve contradictions:
Meta-analytic techniques: Quantitatively synthesizing existing literature to identify moderating variables explaining inconsistent findings
Multi-site collaboration: Implementing standardized protocols across research centers to increase sample size and generalizability
Pre-registration: Documenting hypotheses and analysis plans before data collection to reduce publication bias
Replication focus: Prioritizing direct replication of key findings before extending to new hypotheses
Open science practices: Sharing data, materials, and analysis code to enable verification and alternative analyses
Aryl Hydrocarbon Receptor Interacting Protein (AIP) is a crucial molecular chaperone that plays a significant role in the regulation of the Aryl Hydrocarbon Receptor (AhR) signaling pathway. This pathway is involved in various biological processes, including xenobiotic metabolism, immune response, and cell proliferation. AIP is particularly important in maintaining the stability and proper functioning of AhR, which is a ligand-activated transcription factor.
AIP is a protein composed of 330 amino acids and is encoded by the AIP gene located on chromosome 11q13.3. The protein contains several functional domains, including a tetratricopeptide repeat (TPR) domain, which is essential for protein-protein interactions. The TPR domain allows AIP to interact with various client proteins, including AhR, heat shock proteins (HSP90), and other co-chaperones.
The primary function of AIP is to facilitate the proper folding and stabilization of AhR. In the absence of a ligand, AhR resides in the cytoplasm in a complex with AIP, HSP90, and other co-chaperones. Upon ligand binding, AhR undergoes a conformational change, dissociates from the complex, and translocates to the nucleus, where it dimerizes with the Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT). This complex then binds to xenobiotic response elements (XREs) in the DNA, leading to the transcription of target genes involved in xenobiotic metabolism and other cellular processes .
AIP has been implicated in various physiological and pathological processes. It plays a critical role in the immune system by modulating the activity of AhR, which influences the differentiation and function of immune cells. Additionally, AIP is involved in the regulation of cell proliferation and apoptosis, making it a key player in cancer biology.
Recent studies have shown that AIP is overexpressed in certain types of cancer, such as colorectal cancer, and is associated with poor prognosis. AIP overexpression has been linked to increased tumorigenic and metastatic properties, particularly in highly metastatic colorectal cancer cells. This suggests that AIP may serve as a potential therapeutic target for cancer treatment .
Recombinant AIP is produced using recombinant DNA technology, which involves the insertion of the AIP gene into an expression vector, followed by the expression of the protein in a suitable host system, such as Escherichia coli or mammalian cells. The recombinant protein is then purified using various chromatographic techniques to obtain a highly pure and biologically active form of AIP.
Recombinant AIP is widely used in research to study the molecular mechanisms of AhR signaling and its role in various biological processes. It is also used in drug discovery and development to screen for potential modulators of the AhR pathway.